Procter & Gamble Hygiene and Health Care Limited (PGHH)
🎯 Key Takeaways
- Procter & Gamble Hygiene and Health Care Limited is in a mature growth phase with signs of early stabilization after a period of strategic investment. Management continues to emphasize long-term value creation through its Integrated Growth Strategy despite near-term macro pressures.
- ⚠️ Sustained commodity price inflation could continue to compress margins if cost pass-on is limited.
📖 The Story
Procter & Gamble Hygiene and Health Care Limited is in a mature growth phase with signs of early stabilization after a period of strategic investment. Management continues to emphasize long-term value creation through its Integrated Growth Strategy despite near-term macro pressures. The company is navigating a sales decline while maintaining brand spending, indicating a focus on market share over short-term profitability.
📰 What's Happening
In Q1 2026, sales declined 5% YoY to ₹901 crores, with PAT of ₹126 crores pressured by commodity inflation and higher advertising spend. Management reaffirmed confidence in its strategic framework, citing resilience amid geopolitical challenges. A proposed final dividend of ₹60 per share was announced pending shareholder approval at the upcoming AGM. Additionally, promoter group entity Temple Trees Impex transferred 1.91% of equity to another promoter via an on-market transaction on June 18, 2026, without altering control.
Source: Stock Announcements
🔮 Management Outlook & What's Next
Management expressed continued confidence in the long-term value creation potential of the Integrated Growth Strategy, stating that near-term macro volatility will not deter the execution of their multi-year plan. No specific forward guidance on revenue or margin was provided, but the tone remained steady and forward-looking, emphasizing patience and discipline in capital allocation.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Personal Products
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Godrej Consumer Products Limited | 1.06 L Cr | -234.6 | — | — | — |
| Dabur India Limited | 82,955 | 46.1 | — | — | — |
| Colgate Palmolive (India) Limited | 58,749 | 44.3 | — | — | — |
| Procter & Gamble Hygiene and Health Care Limited | 31,506 | 36.7 | — | — | — |
| Gillette India Limited | 25,438 | 41.0 | — | — | — |
| Emami Limited | 18,684 | 23.6 | — | — | — |
| Cupid Limited | 16,184 | 668.7 | — | — | — |
| Honasa Consumer Limited | 11,518 | 145.1 | — | — | — |
| Bajaj Consumer Care Limited | 7,020 | 58.5 | — | — | — |
| JHS Svendgaard Laboratories Limited | 80 | -5.8 | — | — | — |
⚠️ Risk Factors
1. Sustained commodity price inflation could continue to compress margins if cost pass-on is limited. 2. Increased advertising and promotional spend may not translate into proportional sales growth in the short term. 3. The company’s reliance on a mature product portfolio makes volume growth dependent on market share gains in a competitive FMCG environment. 4. Geopolitical instability and currency volatility pose downside risks to input costs and profitability.
📋 Recent Filings
-
🔴 Financial Results 29 July 2026Procter & Gamble Hygiene and Health Care Limited reported unaudited Q1 2026 results with sales of **₹901 crores**, down 5% YoY, and profit after tax o...
-
Announcement 1 July 2026Procter & Gamble Hygiene and Health Care announced the appointment of Mr. Gopalakrishnan Kalianna as Sales Head effective August 1, 2026, succeeding M...
-
Financial Results 26 June 2026Procter & Gamble Hygiene and Health Care Limited announced that its trading window will close for directors and designated employees starting July 1, ...
-
regulation 31 23 June 2026Procter & Gamble Overseas India B.V. disclosed on April 2, 2026, that it holds 86,01,071 shares representing 51.82% of the paid-up share capital of Pr...
-
🟡 Board Meeting 22 June 2026PGHH proposed a final dividend of **₹60 per share** (face value ₹10) for FY 2025-26, pending shareholder approval at the upcoming AGM, with TDS compli...
-
🔴 Insider Trading 19 June 2026Procter & Gamble Hygiene and Health Care Limited disclosed that promoter group company Temple Trees Impex and Investment Pvt Ltd transferred 6,19,683 ...
-
Announcement 16 June 2026Procter & Gamble Hygiene and Health Care Limited (PGHH) reported flat sales of ₹4,300 crores for FY2026 with 19% YoY PAT growth to ₹850 crores during ...
-
Announcement 16 June 2026Procter & Gamble Hygiene and Health Care Limited presented its investor and analyst meeting on June 16, 2026, highlighting fiscal 2025-26 results with...
-
🔴 Announcement 15 June 2026No summary available
-
🟡 Board Meeting 12 June 2026No summary available
🧠 Analyst's Read
The company is navigating a transitional phase where strategic consistency is being tested by macro headwinds and modest sales contraction. Investors should monitor the trajectory of input cost trends, the effectiveness of advertising spend in driving volume, and the pace of market share recovery in key categories. The upcoming AGM and dividend approval will be key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-04.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when PGHH files new disclosures
Track PGHH filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track PGHH — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research